View Future GrowthRadnostix 過去の業績過去 基準チェック /06Radnostixの収益は年間平均-48.5%の割合で減少していますが、 Life Sciences業界の収益は年間 減少しています。収益は年間3.8% 9.6%割合で 増加しています。主要情報-48.48%収益成長率-50.77%EPS成長率Life Sciences 業界の成長21.51%収益成長率9.62%株主資本利益率-24.59%ネット・マージン-6.95%前回の決算情報31 Mar 2026最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • May 16Radnostix, Inc. announced delayed 10-Q filingOn 05/15/2026, Radnostix, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Oct 20International Isotopes Inc. Appointment of Duke W. Fu to Board as A Director, Effective as of October 10, 2025On October 10, 2025, Dr. Duke W. Fu, age 46, was appointed to International Isotopes Inc.'s Board as a director, with a term effective as of October 10, 2025 and expiring at the Company’s annual meeting of shareholders in 2026 or at Dr. Fu’s earlier resignation or removal. The Board determined that Dr. Fu meets the independence criteria set forth by the Nasdaq Capital Market, and appointed Dr. Fu to the audit committee of the Board. Dr. Fu is a seasoned pharmaceutical executive and Board-Certified Nuclear Pharmacist with over two decades of experience in nuclear medicine, radiopharmaceutical operations, and GMP-compliant manufacturing. Dr. Fu holds a Doctor of Pharmacy and a Master of Business Administration from The University of New Mexico and has a Post Doctorate Specialization as a Board-Certified Nuclear Pharmacist from Purdue University. His career spans CEO and other leadership roles in healthcare distribution, nuclear pharmacy management, and innovative startup scaling, with a proven track record of driving operational excellence, regulatory compliance, and market expansion. Dr. Fu brings deep expertise in cGMP production, and public board directorship. Since 2015, Dr. Fu has served as the chief executive officer of Green Therapeutics and held the positions of interim chief executive officer and chief operating officer of Australis Capital from 2020 to 2022. Previously, Dr. Fu was a managing partner at Biotech Pharmacy, which was acquired by Cardinal Health in 2009. Dr. Fu subsequently continued as a manager at Cardinal Health. In both roles, Dr. Fu oversaw nuclear pharmaceutical manufacturing and the commercial development of novel nuclear imaging and therapeutic agents.お知らせ • May 19International Isotopes Inc., Annual General Meeting, Jul 10, 2025International Isotopes Inc., Annual General Meeting, Jul 10, 2025. Location: 4137 commerce circle, idaho 83401., idaho falls United Statesお知らせ • May 01International Isotopes Inc., Annual General Meeting, Jul 10, 2024International Isotopes Inc., Annual General Meeting, Jul 10, 2024, at 14:00 US Mountain Standard Time. Location: 4137 Commerce Circle Idaho Falls Idaho United States Agenda: To elect four directors to serve for a term of one year and until their successors are elected and qualified; to ratify the appointment of Haynie & Company as independent registered public accounting firm for the fiscal year ending December 31, 2024; and to consider any other business that may properly come before the Annual Meeting.お知らせ • Jul 21+ 1 more updateInternational Isotopes Inc. Appoints Shahe Bagerdjian to Serve as a Member of the BoardThe Board of International Isotopes Inc. appointed Mr. Shahe Bagerdjian to serve as a member of the Board, effective immediately. Shahe Bagerdjian, current President of INIS.お知らせ • Jun 22International Isotopes Inc. (OTCPK:INIS) acquired Nuclear lung ventilation product line from Amici Inc.International Isotopes Inc. (OTCPK:INIS) acquired Nuclear lung ventilation product line from Amici Inc. on June 21, 2023. International Isotopes Inc. (OTCPK:INIS) completed the acquisition of Nuclear lung ventilation product line from Amici Inc. on June 21, 2023.お知らせ • May 25International Isotopes Inc., Annual General Meeting, Jul 12, 2023International Isotopes Inc., Annual General Meeting, Jul 12, 2023, at 14:00 Mountain Daylight. Location: 4137 Commerce Circle Idaho Falls Idaho United States Agenda: To elect three directors to serve for a term of one year and until their successors are elected and qualified; to ratify the appointment of Haynie & Company as our independent registered public accounting firm for the fiscal year ending December 31, 2023; and to consider any other business that may properly come before the Annual Meeting.お知らせ • May 09International Isotopes Inc. Announces Shahe Bagerdjian Appointed as President of the Company, Effective ImmediatelyInternational Isotopes Inc. announced that Shahe Bagerdjian has been appointed as President of the Company, effective immediately. Mr. Bagerdjian comes to INIS from Global Medical Solutions (GMS), a leading manufacturer and provider of radiopharmaceuticals and diagnostic imaging products for applications in nuclear medicine. While at GMS for over 10 years, Mr. Bagerdjian was responsible for implementing the short- and long-term strategy for the business as well as the day to day operations required to carry out those strategies. Mr. Bagerdjian oversaw over 350 employees in 11 different countries, in all functions, including sales, operations, engineering, quality, regulatory, compliance, logistics, finance, legal and human resources. Under his auspices, GMS grew to be the largest company in Southeast Asia in the radiopharmaceuticals and diagnostic imaging industry, and the fourth largest globally in this industry.お知らせ • May 03International Isotopes Inc., Annual General Meeting, Jun 12, 2022International Isotopes Inc., Annual General Meeting, Jun 12, 2022, at 14:00 US Mountain Standard Time. Location: 4137 Commerce Circle Idaho Falls Idaho United States Agenda: To consider and discuss about electing 3 directors to serve for a term of one year and until their successors are elected and qualified; to ratify the appointment of Haynie & Company as independent registered public accounting firm for the fiscal year ending December 31, 2022; to hold an advisory vote to approve the compensation of named executive officers; to approve an amendment to Restated Certificate of Formation, as amended, to effect a reverse stock split of the outstanding shares of common stock by a ratio of not less than 1-for-20 and not more than 1-for-150 at any time, with the exact ratio to be set at a whole number within this range by the Board of Directors in its sole discretion; to consider any other business that may properly come before the Annual Meeting; and thereof.お知らせ • Feb 24Pharmalogic Idaho, LLC completed the acquisition of Certain Assets of International Isotopes Inc. from International Isotopes Inc. (OTCPK:INIS).Pharmalogic Idaho, LLC entered into an Asset Purchase Agreement to acquire Certain Assets of International Isotopes Inc. from International Isotopes Inc. (OTCPK:INIS) for $4 million on February 10, 2022. The consideration shall be paid in cash on closing. The transaction is subject to the buyer being satisfied with its due diligence review of the purchased assets and the execution of sublease and transitional services agreements. It is expected to close on or around February 18, 2022. David J. Champoux of Pierce Atwood LLP acted as legal advisor to Pharmalogic Idaho, LLC. Melanie G. Rubocki of Perkins Coie LLP acted as legal advisor to International Isotopes Inc. Pharmalogic Idaho, LLC completed the acquisition of Certain Assets of International Isotopes Inc. from International Isotopes Inc. (OTCPK:INIS) on February 22, 2022.お知らせ • Dec 30International Isotopes Inc. Terminates Manufacturing and Supply Agreement with Progenics Pharmaceuticals, IncAs disclosed in April 2019, International Isotopes Inc. previously entered into a Manufacturing and Supply Agreement with Progenics Pharmaceuticals, Inc. (Progenics), pursuant to which the Company agreed to provide contract manufacturing services to Progenics for certain of its products. On December 21, 2020, the Company and Progenics entered into an agreement, pursuant to which, among other things, the Manufacturing Agreement was terminated effective immediately, Progenics was granted certain access to the company’s facilities to remove specified equipment, and Progenics agreed to make a termination payment consisting of cash and the value of certain equipment. As part of the agreement, Progenics relinquished all claims to improvements made to the Company’s facility and all equipment purchased by Progenics in connection with the Manufacturing Agreement with the exception of certain specified equipment.収支内訳Radnostix の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:INIS 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Dec 2513-18030 Sep 251408030 Jun 251508031 Mar 251408131 Dec 241408130 Sep 241308130 Jun 2412-18131 Mar 2412-18131 Dec 2312-18130 Sep 2312-17030 Jun 2312-17131 Mar 2311-17031 Dec 221107130 Sep 221007130 Jun 221017031 Mar 221016031 Dec 2110-16030 Sep 21916030 Jun 211026031 Mar 21926031 Dec 20926030 Sep 20905030 Jun 209-15031 Mar 209-25031 Dec 199-25030 Sep 199-15030 Jun 1910-25031 Mar 1910-15031 Dec 1810-15030 Sep 1810-14030 Jun 189-35031 Mar 188-35031 Dec 177-45030 Sep 177-35030 Jun 177-24031 Mar 177-24031 Dec 167-24130 Sep 167-24130 Jun 167-24131 Mar 167-23131 Dec 157-23130 Sep 157-23130 Jun 157-130質の高い収益: INISは現在利益が出ていません。利益率の向上: INISは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: INISは利益が出ておらず、過去 5 年間で損失は年間48.5%の割合で増加しています。成長の加速: INISの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: INISは利益が出ていないため、過去 1 年間の収益成長をLife Sciences業界 ( 3.8% ) と比較することは困難です。株主資本利益率高いROE: INISは現在利益が出ていないため、自己資本利益率 ( -24.59% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 13:02終値2026/05/21 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Radnostix, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Mauro SuarezAlliance Global PartnersDavid Matthew KratochvilAlliance Global Partners
お知らせ • May 16Radnostix, Inc. announced delayed 10-Q filingOn 05/15/2026, Radnostix, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Oct 20International Isotopes Inc. Appointment of Duke W. Fu to Board as A Director, Effective as of October 10, 2025On October 10, 2025, Dr. Duke W. Fu, age 46, was appointed to International Isotopes Inc.'s Board as a director, with a term effective as of October 10, 2025 and expiring at the Company’s annual meeting of shareholders in 2026 or at Dr. Fu’s earlier resignation or removal. The Board determined that Dr. Fu meets the independence criteria set forth by the Nasdaq Capital Market, and appointed Dr. Fu to the audit committee of the Board. Dr. Fu is a seasoned pharmaceutical executive and Board-Certified Nuclear Pharmacist with over two decades of experience in nuclear medicine, radiopharmaceutical operations, and GMP-compliant manufacturing. Dr. Fu holds a Doctor of Pharmacy and a Master of Business Administration from The University of New Mexico and has a Post Doctorate Specialization as a Board-Certified Nuclear Pharmacist from Purdue University. His career spans CEO and other leadership roles in healthcare distribution, nuclear pharmacy management, and innovative startup scaling, with a proven track record of driving operational excellence, regulatory compliance, and market expansion. Dr. Fu brings deep expertise in cGMP production, and public board directorship. Since 2015, Dr. Fu has served as the chief executive officer of Green Therapeutics and held the positions of interim chief executive officer and chief operating officer of Australis Capital from 2020 to 2022. Previously, Dr. Fu was a managing partner at Biotech Pharmacy, which was acquired by Cardinal Health in 2009. Dr. Fu subsequently continued as a manager at Cardinal Health. In both roles, Dr. Fu oversaw nuclear pharmaceutical manufacturing and the commercial development of novel nuclear imaging and therapeutic agents.
お知らせ • May 19International Isotopes Inc., Annual General Meeting, Jul 10, 2025International Isotopes Inc., Annual General Meeting, Jul 10, 2025. Location: 4137 commerce circle, idaho 83401., idaho falls United States
お知らせ • May 01International Isotopes Inc., Annual General Meeting, Jul 10, 2024International Isotopes Inc., Annual General Meeting, Jul 10, 2024, at 14:00 US Mountain Standard Time. Location: 4137 Commerce Circle Idaho Falls Idaho United States Agenda: To elect four directors to serve for a term of one year and until their successors are elected and qualified; to ratify the appointment of Haynie & Company as independent registered public accounting firm for the fiscal year ending December 31, 2024; and to consider any other business that may properly come before the Annual Meeting.
お知らせ • Jul 21+ 1 more updateInternational Isotopes Inc. Appoints Shahe Bagerdjian to Serve as a Member of the BoardThe Board of International Isotopes Inc. appointed Mr. Shahe Bagerdjian to serve as a member of the Board, effective immediately. Shahe Bagerdjian, current President of INIS.
お知らせ • Jun 22International Isotopes Inc. (OTCPK:INIS) acquired Nuclear lung ventilation product line from Amici Inc.International Isotopes Inc. (OTCPK:INIS) acquired Nuclear lung ventilation product line from Amici Inc. on June 21, 2023. International Isotopes Inc. (OTCPK:INIS) completed the acquisition of Nuclear lung ventilation product line from Amici Inc. on June 21, 2023.
お知らせ • May 25International Isotopes Inc., Annual General Meeting, Jul 12, 2023International Isotopes Inc., Annual General Meeting, Jul 12, 2023, at 14:00 Mountain Daylight. Location: 4137 Commerce Circle Idaho Falls Idaho United States Agenda: To elect three directors to serve for a term of one year and until their successors are elected and qualified; to ratify the appointment of Haynie & Company as our independent registered public accounting firm for the fiscal year ending December 31, 2023; and to consider any other business that may properly come before the Annual Meeting.
お知らせ • May 09International Isotopes Inc. Announces Shahe Bagerdjian Appointed as President of the Company, Effective ImmediatelyInternational Isotopes Inc. announced that Shahe Bagerdjian has been appointed as President of the Company, effective immediately. Mr. Bagerdjian comes to INIS from Global Medical Solutions (GMS), a leading manufacturer and provider of radiopharmaceuticals and diagnostic imaging products for applications in nuclear medicine. While at GMS for over 10 years, Mr. Bagerdjian was responsible for implementing the short- and long-term strategy for the business as well as the day to day operations required to carry out those strategies. Mr. Bagerdjian oversaw over 350 employees in 11 different countries, in all functions, including sales, operations, engineering, quality, regulatory, compliance, logistics, finance, legal and human resources. Under his auspices, GMS grew to be the largest company in Southeast Asia in the radiopharmaceuticals and diagnostic imaging industry, and the fourth largest globally in this industry.
お知らせ • May 03International Isotopes Inc., Annual General Meeting, Jun 12, 2022International Isotopes Inc., Annual General Meeting, Jun 12, 2022, at 14:00 US Mountain Standard Time. Location: 4137 Commerce Circle Idaho Falls Idaho United States Agenda: To consider and discuss about electing 3 directors to serve for a term of one year and until their successors are elected and qualified; to ratify the appointment of Haynie & Company as independent registered public accounting firm for the fiscal year ending December 31, 2022; to hold an advisory vote to approve the compensation of named executive officers; to approve an amendment to Restated Certificate of Formation, as amended, to effect a reverse stock split of the outstanding shares of common stock by a ratio of not less than 1-for-20 and not more than 1-for-150 at any time, with the exact ratio to be set at a whole number within this range by the Board of Directors in its sole discretion; to consider any other business that may properly come before the Annual Meeting; and thereof.
お知らせ • Feb 24Pharmalogic Idaho, LLC completed the acquisition of Certain Assets of International Isotopes Inc. from International Isotopes Inc. (OTCPK:INIS).Pharmalogic Idaho, LLC entered into an Asset Purchase Agreement to acquire Certain Assets of International Isotopes Inc. from International Isotopes Inc. (OTCPK:INIS) for $4 million on February 10, 2022. The consideration shall be paid in cash on closing. The transaction is subject to the buyer being satisfied with its due diligence review of the purchased assets and the execution of sublease and transitional services agreements. It is expected to close on or around February 18, 2022. David J. Champoux of Pierce Atwood LLP acted as legal advisor to Pharmalogic Idaho, LLC. Melanie G. Rubocki of Perkins Coie LLP acted as legal advisor to International Isotopes Inc. Pharmalogic Idaho, LLC completed the acquisition of Certain Assets of International Isotopes Inc. from International Isotopes Inc. (OTCPK:INIS) on February 22, 2022.
お知らせ • Dec 30International Isotopes Inc. Terminates Manufacturing and Supply Agreement with Progenics Pharmaceuticals, IncAs disclosed in April 2019, International Isotopes Inc. previously entered into a Manufacturing and Supply Agreement with Progenics Pharmaceuticals, Inc. (Progenics), pursuant to which the Company agreed to provide contract manufacturing services to Progenics for certain of its products. On December 21, 2020, the Company and Progenics entered into an agreement, pursuant to which, among other things, the Manufacturing Agreement was terminated effective immediately, Progenics was granted certain access to the company’s facilities to remove specified equipment, and Progenics agreed to make a termination payment consisting of cash and the value of certain equipment. As part of the agreement, Progenics relinquished all claims to improvements made to the Company’s facility and all equipment purchased by Progenics in connection with the Manufacturing Agreement with the exception of certain specified equipment.